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Little is known concerning immunodominance within the CD4 T-cell response to viral infections and its persistence into long-
termmemory. We tested CD4 T-cell reactivity against each viral protein in persons immunized with vaccinia virus (VV), either
recently or more than 40 years ago, as a model self-limited viral infection. Similar tests were done with persons with herpes sim-
plex virus 1 (HSV-1) infection as a model chronic infection. We used an indirect method capable of counting the CD4 T cells in
blood reactive with each individual viral protein. Each person had a clear CD4 T-cell dominance hierarchy. The top four open
reading frames accounted for about 40% of CD4 virus-specific T cells. Early and long-termmemory CD4 T-cell responses to vac-
cinia virus were mathematically indistinguishable for antigen breadth and immunodominance. Despite the chronic intermittent
presence of HSV-1 antigen, the CD4 T-cell dominance and diversity patterns for HSV-1 were identical to those observed for vac-
cinia virus. The immunodominant CD4 T-cell antigens included both long proteins abundantly present in virions and shorter,
nonstructural proteins. Limited epitope level and direct ex vivo data were also consistent with pronounced CD4 T-cell immu-
nodominance. We conclude that humanmemory CD4 T-cell responses show a pattern of pronounced immunodominance for
both chronic and self-limited viral infections and that this pattern can persist over several decades in the absence of antigen.
Immunodominance refers to the proportion of T cells specific fora defined epitope in relation to the entire set of T cells reacting to
a complex antigen (1). For infectious pathogens encoding many
polypeptides, the immunodominance of an open reading frame
(ORF) is the proportion of the total pathogen-specific response
accounted for by T cells reacting with this ORF. Immunopreva-
lence is a related concept, referring to the proportion of a popula-
tion responding to an immunogen (2). The CD8 T-cell response
to complex microbes can show remarkably strong immunodomi-
nance in humans and inbred animals.
As antigen processing differs between T-cell subsets, it is not
clear that immunodominance also applies to CD4 T-cell re-
sponses. ForVV,memoryCD4T-cell responses in inbredmice are
quite polyclonal and do not exhibit dominance. The top 14
epitopes account for only 20% of the total VV-specific CD4 T-cell
response (3). Data for the human CD4 T-cell response to cyto-
megalovirus, in contrast, were somewhat consistent with immu-
nodominance. Subjects recognized a median of 12 ORFs per per-
son (of 213 ORFs studied), with the top 6 ORFs accounting for
about 40% of the overall response (4). In humans, HLA variation
is expected to influence the identity of immunodominant and
immunoprevalent antigens in specific individuals. Model systems
have identified additional factors controlling epitope choice for
CD4 T cells, including naïve T-cell repertoire (5), antigen abun-
dance (6), antigen folding (7), protease processing and epitope-
flanking regions (8), and antigenic competition (9).
Vaccinia virus is an orthopoxvirus that causes an infection that
resolves completely in several weeks in immunocompetent hosts.
CD4 T-cell memory persists for decades despite the absence of
antigen reexposure, but little is known about the detailed archi-
tecture of long-term memory. The monotonic decline of specific
antibody levels supports lack of intermittent boosting (10). VV
has over 200 ORFs, so each human has a myriad of potential CD4
reactive T-cell specificities. Herpes simplex virus 1 (HSV-1) also
has a complex proteome, but in contrast to self-limited VV infec-
tions, HSV-1 infections are chronic with intermittent reactiva-
tions. Following initial epithelial replication, the virus establishes
persistence in the innervating sensory ganglia. Intermittent reac-
tivation of latent HSV-1 in essentially all HSV-1-infected persons
(11) results in periodic viral antigen exposure to HSV-1-specific
memory T cells (12).
To determine the breadth and persistence of CD4 T-cell im-
munodominance in acute and chronic human viral infections, we
compared patterns of CD4 T-cell immunodominance between
recent and remote VV recipients. The immune responses of per-
sons chronically infected with HSV-1 were also investigated as an
example of a chronic, intermittently reactivating infection. The
immunodominance curves obtained were modeled mathemati-
cally, and specific viral proteins that were repeatedly observed to
be immunodominant were also identified. We believe that the
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novel methods used in this report provide the first detailed com-
parisons of immunodominance in the human CD4 T-cell re-
sponse to cleared and chronic large-genome viral infections.
MATERIALS AND METHODS
Participants and specimens.Adults receiving immunizationwithDryvax
vaccine for occupational health, U.S.-born personswith a history of child-
hood vaccination, and adults with HSV-1 infection (13) gave signed in-
formed consent. The University of Washington Institutional Review
Board approved all study procedures. Bloodwas obtained 20 to 60months
after recent VV vaccination. Age was used to estimate time since child-
hood VV vaccination, based on the U.S. vaccination strategy in the 1950s
to 1970s to vaccinate at 3 to 12 months (14). Peripheral blood mononu-
clear cells (PBMC) were cryopreserved after Ficoll enrichment.
Cell and viral culture. VV NYCBH and HSV-1 E115 were cultured
(13). For virus-specific CD4 oligoclonal microcultures (OCM), PBMC
were stimulated 20 h with UV-treated lysates of mock- and virus-infected
cells. Cells were stained for CD8, CD137, and CD4 (BD), washed, and
7-amino-actinomycin D (BD) labeled. Live, CD4, CD8, and CD137
cells were sorted (FACSAria II, BD) and plated at 4 to 8 cells/well with 105
allogeneic gamma-irradiated PBMC. Phytohemagglutinin (PHA) was
used as the primary mitogen (15). This procedure has been shown to
enrich and select virus-specific CD4 T cells (13). Natural human interleu-
kin-2 (IL-2) (Hemagen) was added (32 U/ml) at 48 h. The base T-cell
medium (TCM) has been described (15). Culture medium changes were
done biweekly for 3 weeks. To raise bulk cultures of VV-specific CD4 T
cells, we either used the CD137 stainingmethod detailed above and sorted
live, CD4, CD8, and CD137 cells in bulk and stimulated them iden-
tically or alternatively stimulated whole PBMC with UV-treated vaccinia
virus and supported proliferation with IL-2 as described previously (16).
Antigens. Viral antigens were UV-treated mock-, VV-, or HSV-1-
infected cell sonicates (15). For VV, BSC40 cells were infected at a multi-
plicity of infection (MOI) of 0.01 and harvested at 48 h, while for HSV-1,
Vero cells were infected at anMOI of 0.001 and harvested at 96 h; in both
cases, monolayers showed confluent cytopathic effect by light micros-
copy. Peptides (Sigma, St. Louis, MO) were used at 1 g/ml for intracel-
lular cytokine cytometry (ICC) or cultured enzyme-linked immunospot
assay (ELISPOT) or at 5 g/ml for direct ELISPOT. The VV expression
library and negative-control Plasmodium falciparum and Francisella tula-
rensis ORFs and ORF fragments have been described (6, 13). Controls
included no vector or pXT7 (6). Proteins diluted in TCMwere arrayed in
a 12 by 24 grid and pooled row- and column-wise to give final concentra-
tions of each protein of 1:12,000. Single proteins were tested at 1:4,000.
The HSV-1 ORFeome set (13) proteins were pooled in a 10 by 12 grid as
above and used at similar concentrations. Thirteen-mer peptides overlap-
ping by 9 amino acids (aa) covered VVORFsWR_059 (protein E3L) (17),
WR_129 (A10L), andWR_101 (H3L) (18). Peptides were arrayed in rect-
angular grids (E3L, 8 by 6; A10L, 24 by 12; H3L, 8 by 10) for row- and
column-wise pools.
VV antigen/epitope discovery for bulk cultures. Bulk VV-specific
CD4 T-cell cultures expanded from PBMC were interrogated with both
genomic library-based and full-length ORF methods as described previ-
ously (16, 17). Molecular truncations were made to detect short antigenic
viral polypeptides in initial hits (16, 17). Peptides (13-mer; overlap of 9 aa)
at 1 g/ml that stimulated0.3% of bulk CD4 T cells to express gamma
interferon (IFN-) (17) were scored as reactive.
Immunodominance proliferation assays. For the CD137-enriched
CD4 T-cell OCM, sequential [3H]thymidine proliferation assays (15)
were done. Autologous irradiated PBMC (3 104 to 5 104/well) were
antigen-presenting cells (APC), [3H]thymidinewas added after 36 to 60 h,
and cells were harvested 6 to 18 h later. To interrogate a viral ORF matrix
set,50% of responder OCM cells were split into 24 (HSV-1) or 38 (VV)
wells of 96-well U-plates. Recombinant antigen pools and UV-mock and
-virus controls were tested. When the [3H]thymidine data returned, the
remaining OCM cells were plated into enough wells tomatch the product
of the number of positive-row and -column pools, plus two. Single anti-
gens from intersections of positive rows/columns were tested. For one
person with many OCM reactive with VV proteins E3L or H3L, residual
cells were used in a final [3H]thymidine assaywithmatrix-arrayed peptide
pools. Cells from multiple OCM reactive with VV protein A10L were
combined into 2 pools prior to peptide analysis.
T-cell assays. Direct ex vivo 20-hour PBMC IFN-, IL-2, and tumor
necrosis factor alpha (TNF-) ICC for responses to whole VV included
costimulatory monoclonal antibodies (MAbs) (anti-CD28 and -CD49d)
and brefeldin A (17). Staining (17) used Violet live/dead and fluoro-
chrome-conjugatedMAbs: CD8PerCP-Cy5.5, CD4 allophycocyanin-H7,
CD3 energy-coupled dye (phycoerythrin [PE]-Texas Red), IFN- PE-
Cy7, IL-2 PE, and TNF- fluorescein isothiocyanate (FITC) (all BD).
Gating used the lymphocyte forward/side scatter window, followed by live
cells, CD3 cells, and then CD4 CD8 cells. Net percentages of cyto-
kine-positive live CD3CD4CD8 cells were calculated by subtracting
mock responses. To use ex vivoPBMCCD137 expression for analysis, cells
were stimulated 20 h without costimulatory MAb/brefeldin A, stained
withViolet live-dead andCD137APC,CD8PerCP-Cy5.5, andCD4FITC,
washed, fixed, and analyzed. Gating used the lymphocyte forward/side
scatter window, followed by live cells and then CD3 CD4 CD8 cells.
The net percentages of live CD4 CD8 CD137 lymphocytes were an-
alyzed by subtracting values from mock-stimulated cells. Direct ex vivo
IFN- ELISPOT (17) results are mean (of duplicate) spot-forming units
(SFU)/106 PBMC minus mean background. For IFN- ICC tests of ex-
panded bulk responders, we incubated 3 105 responders with an equal
number of carboxyfluorescein succinimidyl ester (CFSE)-labeled autolo-
gous PBMC for 6 h with costimulatory MAb and brefeldin A. Staining
used surface CD3 APC, CD4 PerCP, and intracellular IFN- PE. Gating
used the lymphocyte forward/side scatter area followed byCD3 cells and
then dump-gated the CFSE cells used as APC (19).
Statistics. Immunodominance was estimated by calculating the per-
centages of total CD4 ORF level antigen responses for the top four viral
ORFs. Quantitative immunodominance measures were modified magni-
tude-breadth analyses (20). For each participant, the log10 cumulative
number of ORF level responses was plotted versus the linear cumulative
breadth, starting with the most dominant response, with both measures
normalized to percentages of the total for that person. The X-Y data sets
were natural log fit (Excel; Microsoft, Redmond,WA) with default trend-
line parameters. Reported variables are from resultant curves, y 	
m[ln(x)] b, and R2 values. Integrated analyses of the data from the VV
(n 	 8) and HSV subjects (n 	 4), considered groups, were done by
summing either the number of CD4 responses per rank or the number of
CD4 responses per ORF, excluding ORFs with 3 or fewer CD4 cells per
person. Summed responses were plotted versus the log10 of the rank. The
X-Y data sets were fit to a linearmodel. Calculated values from curves [y	
m(x) b] and R2 values were recorded.
RESULTS
CD137 upregulation identifies virus-specific CD4 T cells. We
recruited persons with a history of recent (n	 4) or distant (n	
4)VV vaccination and 4 persons seropositive forHSV-1 (Table 1).
A small proportion of live, CD4 T cells expressed intracellular
IFN-, TNF-, or IL-2 after 20 h of stimulation with whole virus
(Fig. 1A; Table 2). We have previously shown for both vaccinia
virus andHSV that these cytokine-positive cells contain amixture
of monofunctional cells expressing one cytokine and polyfunc-
tional cells expressing two or three of the cytokines tested (17,
23). We tested CD137 responses side by side and observed
similar responses (representative data are shown in Fig. 1B).
Recently, we reported that CD137 could also be used to sort
and expand memory human CD4 T cells reactive with HSV-1
or recent vaccinia virus vaccination (13). To determine if
CD137 could be used to enrich VV-specific CD4 T cells from
Jing et al.
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persons several decades after vaccination, we repeated bulk
level CD4 T-cell analyses using the exact same method. Again,
VV-reactive CD4 cells in the CD137high origin cultures were
considerably enriched, with the expanded, bulk, T-cell lines
showing large IFN- responses to whole VV antigen (represen-
tative data are shown in Fig. 1C).
Assessing CD4 T-cell dominance and diversity for VV and
HSV-1 antigen recognition at the functionally clonal level. To
assess immunodominance at the single-cell level, we then modi-
fied this method for both recent and distant vaccinees by sorting
CD137high immediately after a short, 18-hour ex vivo stimulation
into near-clonal cultures. Functionally clonal responses within
these microcultures were then dissected via multiplexed fine-
specificity analyses using a complete protein set. We distributed
CD3 CD4 CD137high cells immediately after sorting into mi-
crowells at 4 to 8 cells/well and stimulated the cells with a nonspe-
cific mitogen, PHA (24). The resultant progeny of the few sorted
PBMC/well were termed oligoclonal microcultures (OCM).
These cells reliably expanded to several hundred thousand daugh-
ter cells by day 14, at which time readout assays were initiated.
OCM cells remained viable and antigen reactive through day 23,
permitting initial, confirmatory, and downstream assays without
the need for any additional exposure to a mitogen.
The specificities of the oligoclonal populations in the OCM
wells were obtained using two sequential assays. We first interro-
gated 60 to 72 OCM per person against the entire respective virus
proteome set, represented as protein pools from rows and col-
umns in a matrix. It was quite infrequent to observe a positive
response to whole-virus lysate in the first assay but not to observe
at least one positive-rowpool and -columnpool of individual viral
proteins. Less than 10% of virus-reactive OCM for the set of 12
subjects studied had this pattern. Intersection(s) of reactive
row(s) and column(s) each identified a candidate reactive viral
ORF (Fig. 2A). To confirm antigen specificity, each candidate was
tested in the second assay in a subset of 21 to 60 OCM per person.
The criteria for selecting OCM for the secondary assay were a
positive response to whole-virus lysate, at least one column and
row pool in the first assay, and the physical presence of enough
healthy cells as assessed by light microscopy to permit an esti-
mated 5,000 cells per well to be added to the second assay. We
observed large signal-to-noise ratios at both assay stages (Fig. 2B
and C). Positive-control whole-virus responses were brisk.
Among the 12 persons, the median number of reactive ORFs per
OCMwas 2 (average
 standard deviation, 2.2
 1.15; range, 1 to
6). The OCM were therefore proven to be monospecific to oligo-
nucleotide specific for virus-reactive CD4 T cells.
Immunodominance architecture of the virus-specific CD4
T-cell response.We studied 21 to 60 virus-reactive OCMper per-
son in the initial assay, yielding fine-specificity data for 37 to 153
virus-specific CD4 T cells per participant in the second assay (Ta-
ble 2). On an integrated basis, we obtained 1,134 unique antigen
level hits for virus-specific CD4 T cells among the 12 study sub-
jects, on average determining the ORF level specificities of 94 vi-
rus-specific CD4 T cells per person. The positive responses were
displayed as histograms with each bar representing a viral ORF
and ordered from most- to least-abundant responses. Generally,
pronounced immunodominance was displayed by 2 to 4 viral
ORFs per participant (Fig. 3). Several proteins were then recog-
nized in a subdominant fashion, followed by a long tail of viral
TABLE 1 Participants studied in this report
Participant
IDa
VV
vaccination
historyb
HSV-1/HSV-2
serostatusc HLA class II typed
V3 2, 30 mo NAe DRB1*15, *03, DQB1*0201, *0602
V8 2, 20 mo NA DRB1*1201, *0405, DQB1*0301, *0401
V9 2, 44 mo NA DRB1*1501, *0401/33, DQB1*0301, *0602
V12 1, 60 mo NA DRB1*11:01, *11:04, DQB1*03:01
V16 1, 49 yr NA DRB1*11:01, *15:02, DQB1*03:01, *06:01
V17 1, 41 yr NA NDf
V18 1, 57 yr NA DRB1*04:04, *15:01, DQB1*03:02, *06:02
V19 1, 46 yr NA DRB1*04:01, *07:01, DQB1*02:02, 03:02
H1 NA Pos/neg DRB1*0701, DQB1*0202
H5 NA Pos/pos DRB1*0101, *0301, DQB1*0201, *0501
H6 NA Pos/pos DRB1*1104, *1401, DQB1*0301, *0503
H15 NA Pos/neg DRB1*07:01, *12:01, DQB1*03:01, 03:03
a V refers to VV with participants V3, V8, V12, and V9 from previous reports (6, 16,
21), with V16 through V19 new to this report. H refers to HSV-1 with persons H6, H5,
and H1 from previous reports (13) and H15 new to this report.
b Number of lifetime VV vaccinations and interval in months between the most recent
vaccination and phlebotomy (V3 through V12) or chronologic age at phlebotomy (V16
through V19).
c Pos and neg, presence and absence, respectively, of type-specific IgG by immunoblot
assay (13).
d HLA types reflect the nomenclature current at the time the typing was performed. An
explanation and reconciliation tools are available (22).
e NA, not applicable.
f ND, not done.
FIG 1 CD137 upregulation identifies virus-specific CD4 T cells. Direct ex vivo PBMC expression profiles of cytokines (A) and CD137 (B) from remote VV
vaccinee V16 tomock and vaccinia virus (VV) antigens. Percentages of positive cells, gated on live CD3CD8CD4 cells, are provided. (B) Rectangles are gates
for sorting CD137low or CD137high CD4 T cells. (C) IFN- expression of bulk cultures of CD137low- or CD137high-sorted CD4 T cells tested to mock and VV
antigens using autologous APC. Numbers represent the percentages of cells in the upper right quadrant.
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proteins recognized by a single CD4 T-cell. The top 4 viral ORFs
per person drove the responses of 28 to 64% of CD4 T cells within
a person.
The pattern of reactivity was independent of the virus assayed
or time since VV vaccination (Fig. 3). The cumulative immu-
nodominance distributions were remarkably similar in shape.
Each breadth-dominance curve closely fit a logarithmic equation
of the form y	 [m(ln) b] with R2 values near 1.0. The equation
parameters, particularly the “m” term describing the steepness of
the curve, were similar regardless of the duration of CD4memory
for VV and for VV in comparison to HSV-1. This indicates a
similar proportional drop-off in abundance with decrease in rank
for both HSV-1 and VV and regardless of time since infection for
VV.
Next, we summed the total number of CD4 T cells within each
rank for all participants by group (VV or HSV-1) and plotted the
log of this sum versus the log rank (Fig. 4). These plots approxi-
mated linearity for the 8 VV participants (R2	 0.96) and 4HSV-1
participants (R2 	 0.95) and fit Zipfian distributions (25) with
slopes equaling 0.7 and 0.8, respectively. This Zipf distribu-
tion suggests that the relative abundance of CD4 T cells reactive
with a particular ORF can be predicted based entirely on its rank
and the slope of the log-log plot (Fig. 4A). The plots of recent and
distant VV recipients were superimposed, implying equivalent
rank-abundance traits between groups (Fig. 4B).
Breadth of the virus-specific CD4 response. The CD4 T-cell
breadth per person ranged from 25 to 48ORFs in recent vaccinees
and from 38 to 44 ORFs in distant vaccinees. For HSV-1, the CD4
T-cell breadth ranged from 20 to 42 HSV-1 ORFs. Each person
recognized 11% to 22%of theVVORFs tested. In comparison, for
HSV-1, participants recognized a higher percentage of the HSV-1
ORFs, ranging from 27% to 57% of the 74 HSV-1 ORFs studied.
CD4 T cells may recognize one or more peptides within a pro-
tein. To investigate whether responses that were dominant at the
ORF level also showed immunodominance at the peptide level, we
tested overlapping peptides from three VV proteins that showed
immunodominance. OCM from remote VV subject V17, reactive
with A10L (WR_129) or E3L (WR_059) were decoded to the 13-
mer peptide level, as were OCM from remote VV subject V18,
reactive with H3L (WR_101). For E3L, with 48 peptides tested, 10
of 10 OCM reacted with E3L peptides 49 to 61 (KALYDLQRSAM
VY). For H3L, 80 peptides were tested, and the data were consis-
tent with the recognition of two overlapping 13-mers, H3L 221 to
233 (NEMKINRQILDNA) and H3L 225 to 237 (INRQILDNAA
KYV) by each of 11 distinct OCM. This implies recognition of one
epitope approximated by INRQILDNA (H3L 225 to 233). Simi-
larly, two pools, made from cells from 10 or 8 OCM reactive with
full-length A10L, each reacted with only one peptide, A10L 73 to
85 (GINYLIDTTSREL), among the 288 13-mers tested. Overall, a
single epitopewas internally dominant within each immunodom-
inant ORF tested.
CD4 immunodominance directly ex vivo. Separately, we used
published (16, 17)methods to defineVVCD4T-cell antigens, and
then epitopes, for participant V9. In preliminary work, a VV-
reactive bulk CD4 T-cell line from this subject recognized 23 VV
polypeptides (not shown). Overlapping peptides were obtained
for these ORFs, and at least one reactive peptide was found per
ORF when queried with the bulk CD4 T-cell line using IFN-
readouts (not shown). We then examined direct ex vivo PBMC
responses to these CD4 antigenic peptides. We observed that re-
sponses to peptides in 9 of these ORFs were detectable at 5
SFU/106 PBMCwith an IFN- ELISPOT readout.When arranged
by magnitude, the peptide immunodominance pattern (Fig. 5)
was similar to that observed for vaccinia virus ORFs using the
indirect CD137 method.
Characteristics of immunodominant viral proteins. Several
of the VV and HSV-1 proteins with in-person immunodomi-
nance (Table 3) were long polypeptides that were also abundant in
purified virions (26, 27). Four of the nine most-abundant VV
virion proteins, encoded by WR_129, WR_122, WR_148, and
TABLE 2 Characteristics of OCM and CD4 breadth and immunodominance data derived from CD137high PBMC
Participant
IDa
Direct ex vivo% of live CD4s
In vitro-expanded cells, % CD4
IFN-
OCM
studiedb
ORF level
hitsc
CD4
breadthd
% Top 4 ORF
dominancee
CD137high
origin CD137low origin
CD137 IFN- IL-2 TNF- Mock Virus Mock Virus
V3 1.09 0.41 0.25 0.29 NDf ND ND ND 23 71 33 28
V8 0.42 0.07 0.07 0.18 ND ND ND ND 60 84 25 39
V9 1.18 0.27 0.22 0.35 ND ND ND ND 48 117 44 35
V12 1.1 0.87 0.76 1.13 ND ND ND ND 52 153 48 64
V16 0.15 ND ND ND 0.38 14.1 0.2 0.27 52 105 38 32
V17 0.12 ND ND ND 0.30 5.25 0.149 0.153 54 95 44 39
V18 0.02 ND ND ND 0.16 1.91 0.08 0.06 38 116 38 42
V19 0.06 ND ND ND 0.45 31.5 0.21 0.28 55 95 38 33
H1 0.17 ND ND ND ND ND ND ND 21 37 20 49
H5 0.24 ND ND ND 0.18 15.14 0.13 0.52 34 113 42 32
H6 0.53 ND ND ND 0.22 19.1 0.19 0.75 45 113 35 44
H15 0.06 ND ND ND ND ND ND ND 35 75 32 30
a See Table 1 for participant and viral infection data.
b Number of OCMs with positive row and column pool level responses to viral antigens used for assays with single viral proteins.
c Number of positive reactions between individual OCMs and single viral proteins.
d Number of unique viral ORFs recognized by the integrated group of OCM.
e Percentage of ORF level hits triggered by the four most frequently recognized single viral proteins.
f ND, not done.
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WR_101, were immunodominant in at least two persons. Simi-
larly, the envelope HSV-1 glycoproteins gB (encoded by gene
UL27) and gD (encoded by US6), similar in sequence to those of
HSV-2 vaccine candidates (28), were frequently immunodomi-
nant. The HSV-1 immediate early regulatory protein ICP4 (RS1)
is also abundant in virions (27) and was dominant in each of 4
subjects. There were some exceptions to this pattern, as occasion-
ally short, nonstructural proteins also displayed immunodomi-
nance. For example, the VV protein encoded by WR_059 (E3L),
which was immunodominant in four persons, is only 190 aa long
andmay be absent from virions (26, 29). The VV protein encoded
byWR_118 (D13L), dominant in 5 persons and prevalent in 8, is
present in trace amounts in virions. Overall, there were 9 VV pro-
teins detected as reactive in at least 75% of the subjects regardless
of rank, encoded by the following genes: WR_118 (8 persons),
WR_072 and WR_122) (7 persons), and WR_052, WR_070,
WR_091,WR_098,WR_101, andWR_129 (6 persons each).WR_
118 is also known as the target for rifampin resistance. WR_072
encodes a single-stranded DNA-binding phosphoprotein that is
also known as I3L. Among the remaining frequently immuno-
genic vaccinia virus proteins, WR_070 (I1L) and WR_091 (L4R)
are both DNA-binding proteins, WR_098 (J6R) is a DNA-depen-
dent RNA polymerase, WR_052 (F13L) and WR_101 (H3L) are
envelope proteins, and WR_129 (A10L) is a core protein. The
HSV-1 UL40 and US12 proteins, undetectable in virions, could
show immunodominance; the latter is quite short. We also noted
that identical HSV-1 and VV ORFs could be immunodominant
for CD4 responses in persons who did not share HLA class II loci
(Tables 1 and 3).
DISCUSSION
We report proteome-wide examination of the fine architecture of
human CD4 T-cell immunodominance for two complex mi-
crobes. Contrary to VV CD4 experiments in mice (3), we found
pronounced immunodominance in recent VV vaccinees. Surpris-
ingly, broad tails of subdominant and low-abundance responses
were maintained in remote VV vaccinees, such that the architec-
ture of the CD4 T-cell dominance curves were mathematically
indistinguishable in recent and remote vaccinees. We conclude
that a single antigen exposure to VV primes a diverse CD4 mem-
FIG 2 Schema and representative raw data for oligoclonal microcultures. (A) Method of arraying VV polypeptides into 12 rows and 24 columns. Some pools
contained negative controls (left). Sample [3H]thymidine proliferation data from one OCM are shown on the right. Row 2C and column 7 are positive.
Confirmatory proliferation data using just the VV antigen at the row 2C-column 7 intersection, shown in red, were positive (not shown).Whole-UV-VV control
at lower right. (B) Representative row and column [3H]thymidine proliferation data from anOCMwith a complex pattern of reactivity, showing 4 positive-row
and 5 positive-column pools. There are 20 candidate antigenic VV proteins at the intersections. Positive-control UV-VV at right. (C) Each candidate antigenic
polypeptide was assayed by [3H]thymidine proliferation. There were six hits. The row 2C pool contained two positive antigens, 2C1 and 2C2.
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FIG 3 CD4 T-cell reactivity to VV (A) and HSV-1 (B) proteins. Histograms represent one person each with recent (“recent vaccinia”) or remote (“remote
vaccinia”) VV vaccination (V12 and V16) (A) or HSV-1 infection (B). The y axes carry the numbers of separate oligoclonal microcultures (OCM) cultured from
CD137high-sorted virus-specific PBMC-derivedCD4T cells reactingwith each viral protein. The x axes carry the names or numbers of individual viralORFs using
standard nomenclature. Viral proteins are ordered frommost to least dominant. Insets are breadth-dominance curves from each histogram. The x and y axes are
the cumulative percentages of the CD4T-cell breadth and theORF level hits, respectively. Trend line natural log fits display parameters andR2 with experimental
data.
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ory that persists for decades. A similar immunodominance pat-
tern was noted for HSV-1-specific CD4 T cells, despite the very
different pathogenesis of HSV infections. Periodic reexposure to
endogenous HSV-1 antigens after the infection is established does
not seem to fundamentally influence the nature of CD4 T-cell
immunodominance.
There are several novel aspects of this report. CD4 T-cell anti-
gens and epitopes have previously been reported for both VV and
HSV-1 (13, 30–33), but their immunodominance has not been
rigorously addressed in humans. We are aware of one study that
measured human CD4 T-cell responses to VV proteins directly ex
vivo, but the protein space investigated covered only 4 VV mem-
brane proteins (34). ELISPOT for IFN-, the assay used in that
report, may fail to detect low-abundance or functionally ex-
hausted responses. In contrast, we investigated the entire pro-
teomes of two microbes. Earlier CD4 T-cell studies of VV and
HSV-1 (6, 13, 16, 17) used fundamentally different responder cell
populations, namely, highly polyclonal cell lines. These responder
cells were suitable for scoring individual proteins as reactive or
nonreactive but not appropriate for counting individual virus-
specific CD4 T cells. In this report, we interrogate responder cell
cultures that are conceptually clonal, using combinatorial meth-
ods to detect reactivity with near-complete viral proteome sets.
This allows actual determination of the number of CD4 T cells
reactive with each viral ORF and thus precise detection of immu-
FIG 3 (Continued)
FIG 4 (A) Abundance rank plots of log abundance per rank versus log rank in
eight vaccinia virus recipients and four HSV-1-infected persons. The x axis
represents the log values of rank; the y axis represents the log values of abun-
dance per rank in each group. (B) Abundance rank plots of log abundance per
rank versus log rank in four recent and four distant vaccinia virus recipients;
the x axis represents the log value of rank; the y axis represents the log value of
abundance per rank in each group.Gray lines represent the linear fit to the data
with the y-intercept equalized to the data. Reactive antigenswith an abundance
of 3 or fewer were not included in the plots.
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nodominant antigens and dominance patterns in circulating CD4
T cells.
In quantitative analysis, we were not able to distinguish the
T-cell CD4 immunodominance architecture between recent and
past VV vaccinees. Both groups of persons had dominant re-
sponses to a few antigens and a wide set of subdominant and
minority responses. VV ORF-reactive CD4 T cells were rank or-
dered per Zipf’s law, a distribution that assumes that the abun-
dance of T cells specific to each antigen is amathematical function
of antigen rank within each person. The similarity of the slopes of
the rank dominance curves in Fig. 4 implies that the architecture
of the immunodominance hierarchy is the same for both recent
and distant VV infections and for VV and HSV-1 infections. The
reason for this precise structure of antigen specificity among CD4
T cells is unknown. Equal priming of T cells reactive with many
antigens, followed by differential rates of CD4 T-cell decay, is one
possibility. This seems unlikely, because over decades following
VV exposure, the rather broad tails of CD4 T-cell responses that
we observed would be expected to narrow, unless the rates of
clonotype decay themselves were each dynamic and slowed over
time as T cells with defined specificities became rarer. Stochastic
effects could be important if chance events during the first contact
between a naïve T cell and APC predict proliferation and survival.
If these initial contacts were commoner for some antigens than
others, this stochastic theory could be reconciled with our obser-
vation that the same VV antigens tend to be immunodominant in
multiple persons. A higher number of initial APC-naïve cell con-
tacts would lead to a higher probability of advantageous priming
events. We previously observed that immunoprevalent VV CD4
T-cell antigens tended to be abundant virion envelope and capsid
proteins (6, 16, 17), which might be expected to give rise to abun-
dant peptide-HLA complexes on APC.
In some model systems, APC process or retain certain HLA-
peptide complexes more efficiently expressed than others (35).
This competition presumably results in a selective advantage for
early expansion and higher persistent levels of T cells specific for
these antigens.While protein abundance could be one factor feed-
ing into the number of HLA-peptide complexes, we noted exam-
ples for both VV and HSV-1 in which viral proteins that were of
very low abundance or undetectable in virions were nonetheless
immunodominant, often in several people (Table 3). A mathe-
matical model based on murine influenza data predicted that dif-
ferential antigen expression explains CD8 T-cell immunodomi-
nance after a secondary exposure to virus but not following
primary infection (36). Our results revealed that CD4 T-cell im-
munodominance established after a single primary antigenic ex-
posure to VV is partially but not completely explained by antigen
abundance.
Naïve T-cell clonotype abundance seems to be predictive of
immunodominance in inbred mice (37) and may also operate on
anHLA allele-specific basis in humans (38), albeit there are exam-
ples of inverse relationships between naïve and memory abun-
dance for CD4 T cells (39). This factor alone would not explain
our data indicating that the same antigens can be dominant in
subjects who do not share HLA alleles. Our subjects were quite
diverse for HLA class II alleles and therefore would be expected to
have diverse naïve T-cell repertoires. To address the issues of HLA
type and the naïve repertoire, we would need to determine virus-
specific fine specificity to the levels of exact peptides, HLA restric-
tion, and even T-cell clonotypes and compare memory to naïve T
cells.
It is clear from our data that memory CD4 T-cell responses to
VV are extraordinarily long-lived. The contributors to memory
T-cell survival in the absence of antigen are incompletely under-
stood.Memory CD4 T cells can express receptors for the survival/
proliferation cytokines IL-7 and IL-15 (40). Intercurrent infec-
tions seem to perturb CD4 less than CD8 memory (41), but it is
possible that coinfections such as Epstein-Barr virus (EBV) or
influenza virus infections could influence dominance via heterol-
ogous immunity (42).
Limitations of our study include the number of persons stud-
ied, potential bias introduction by CD137 selection or prolifera-
tion assays, and impurities and small gaps in the viral proteome
sets. Each of the fourHSV-1 persons studied recognizedUL27 and
RS1, but if we had studied more persons, exceptions to this high
population prevalencemight emerge. Each of the 8VV-vaccinated
persons had a similar CD4 T-cell immunodominance architec-
ture, although variation in dominance patterns and in the identity
of dominant antigenswould be likely in a larger population. There
are no data indicating that any T-cell subsets fail to upregulate
CD137 after TCR ligation and would thus be excluded from our
data, albeit this is possible. Because our restimulation cultures
contained only 4 to 8 seed cells, cell competition during the ex-
pansion phase was minimized. We very frequently detected sev-
eral specificities from each microculture well, indicating that at-
trition due to failure to proliferate was quite uncommon among
the sorted CD137high cells. Memory CD4 T cells exist in several
subsets, with effector-memory and effector cells having less pro-
liferative potential (43). MAb ligation of CD137 is strongly co-
stimulatory for cell subsets thought to be functionally exhausted
(44, 45). Future experiments with sorted CD4 T-cell responder
subsets should be able to address this hypothesis.
FIG 5 Immunodominance architecture of VV-specific CD4 responses in par-
ticipant V9 measured by ex vivo IFN- ELISPOT. Bar labels are names of VV
WR ORFs and amino acid numbers of peptides. The inset shows the breadth-
dominance curves corresponding to the histogram. The x axis represents the
cumulative percentage of CD4 breadth. The y axis represents the cumulative
percentage of CD4 ORF level hits. Peptides are ordered as in the histogram
from most to least dominant. The trend line is a natural log fit curve with
parameters and R2 with experimental data displayed.
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It is possible that we detected progeny cells resulting from in
vitro priming rather than memory recall. Arguing against this, in
vitro priming typically requires specialized APC and repeated cy-
cles of antigen exposure and leads to very low responder cell fre-
quencies (46).We have yet to detect specific CD137 expression by
CD4 T cells from persons who were seronegative for vaccinia vi-
rus, so use of thismethod to probe the naïve repertoire is currently
out of reach. We have previously shown that a minority of HSV-
1/HSV-2 doubly seronegative persons, highly exposed to HSV-1,
had direct ex vivo cytokine and CD137 responses to HSV-1 (13).
The reason for this reactivity is unclear and could represent sen-
sitization to noninfectious virus via interpersonal contact or
cross-reactivity with other herpesviruses. We also observed cyto-
kine reactivity to HSV peptides at relatively high levels directly ex
vivo in a small number of HSV-1/HSV-2 doubly seronegative per-
sons who were sexual partners of HSV-2-infected persons (47).
The direct ex vivo nature of these observations in overnight assays
is not consistent with in vitro priming as a cause of the positive
T-cell responses in these cases for seronegative persons. For vac-
cinia virus, we have never observed a positive cytokine response
TABLE 3 VV and HSV-1 proteins showing within-person immunodominance
Virus ORFb
Participant IDa
VV recent VV remote HSV-1
V3 V8 V9 V12 V16 V17 V18 V19 H1c H5 H6 H15c
VV
WR_118 x x x x X
WR_059 x x x x
WR_098 x x x x
WR_101 x x x
WR_129 x x x
WR_072 x x
WR_095 x x
WR_122 x x x
WR_148 x x
WR_020 x
WR_025 x
WR_065 x
WR_029 x
WR_081 x
WR_083 x
WR_091 x
WR_102 x
WR_103 x
WR_106 x
WR_149 x x
WR_167 x
WR_167 x
WR_174 x
WR_181 x
WR_184 x
WR_194 x
WR_200 x
HSV-1
UL27 x x x x
RS1 x x x x
US6 x x x
UL21 x x
UL26 x x
UL13 x
UL22 x
UL23 x
UL25 x
UL40 x
UL46 x
US12 x
RL2 x
a See Table 1 for detailed participant and viral infection or vaccination information.
b Identity of viral ORFs, using VV strain WR or HSV-1 strain 17 nomenclature, encoding proteins scoring in the top first to fourth ranks for each person, in rank order. Proteins
recognized by an equal number of CD4 clonotypes were each included.
c Participants H1 and H15 had flat breadth-dominance curves, and only the top three ranks are included.
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directly ex vivo (16). Because the CD137 purification method in
this report also sorts cells immediately after direct ex vivo stimu-
lation, we think it is unlikely that responses would be induced by
in vitro priming. It is also possible that CD137 and the cytokine
assays detect different cells. For example, there could be some
degree of bystander activation for either the CD137 or cytokine
readouts. Further research on these points is needed.
The viral lysates used for the initial PBMC restimulation donot
appear to be a source of bias with regard to incomplete expression
of the viral proteomes, as reflected by the detection of responses to
both structural and nonstructural proteins for both viruses. Sim-
ilarly broad recognition of structural and nonstructural proteins
was noted in earlier CD4 research using the same lysate protocols
(6, 13). We did note that up to 10% of OCM that recognized
whole-virus lysate did not react with our recombinant protein
pools, such that some of the viral proteins may have been present
in low or poorly immunogenic forms in these pools, or possibly
that cryptic ORFs or epitopes requiring posttranslational modifi-
cations were recognized by rare CD4 T cells in PBMC. TheHSV-1
protein set used is not quite complete (13), andwe have previously
documented the presence of cryptic VV ORFs in our CD8 work
(21). It is possible that the same T-cell clonotype could be recog-
nizingmore than one viral protein and thus give two positive ORF
level readouts rather than one, but CD4 T cells typically require
near identity at amino acids 1, 4, 6, and 9 to bind to HLA class II
and also similar amino acids to face up to the T-cell receptor (48),
such that this is quite unlikely, especially because the HSV-1 and
VV genomes tend not to contain families of highly sequence-re-
lated proteins. Finally, we do not yet know how reproducible our
immunodominance hierarchies would be if assayed multiple
times on the same PBMC specimen. The identity of the dominant
within-person ORFs would be less likely to show assay-to-assay
variation thanwould the detection of the very subdominant ORFs
detected only once each, due to sampling of rare cells in PBMC.
The viral proteins used in this report were prepared using high-
throughput methods suitable for complex pathogens. Because the
cells are interrogated in near-clonal conditions, some variation in
the individual viral proteins may be tolerable without altering the
dichotomous, yes/no readouts for each T-cell microculture. Our
digital data set scored1,000 near-clonal CD4 T-cell populations
as reactive with single antigens in assays with very high signal-to-
noise ratios. Protein purity is thus less essential than in analog
assays performed with polyclonal responders occurring at low
abundance in a background of bystander cells, such as direct
PBMC assays. In contrast to many reports, we made proteins in
vitro rather than within Escherichia coli or other host cells, reduc-
ing contamination with microbial innate immunity agonists and
bystander proteins. The vaccinia virus and HSV-1 protein sets are
not yet pure enough for direct ex vivo studies, a future goal.We did
perform limited direct ex vivo work and found an immunodomi-
nance hierarchy similar to those observed with the OCMmethod.
In subject V9, studied by both methods, there was not a strict
correlation between the dominance of ORF98 at the whole ORF
level and rank dominance of one constituent peptide, but thismay
be due to the large size of this ORF (1,286 amino acids) and the
presence of additional peptide epitopes within this protein.
In conclusion, the humanmemory CD4 T-cell responses, both
shortly and decades after infection with the completely cleared
agent VV and in response to the chronic pathogen HSV-1, have
mathematically near-indistinguishable patterns of immunodomi-
nance. This implies extremely efficient maintenance of even low-
abundance T cells in the absence of antigen. The CD4 T-cell re-
sponse invariably resembles the better-studied CD8 T-cell
compartment, dominated by a few antigens that also tend to be
immunoprevalent and are thus rational vaccine candidates. The
net pattern of CD4 T-cell immunodominance appears to be an
intrinsic property of this complex biological system.
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